Literature DB >> 26181443

Current chemotherapies for advanced hepatocellular carcinoma.

Kazuhiro Nouso1.   

Abstract

The incidence of hepatocellular carcinoma (HCC) increases with the advancement of chronic liver diseases such as hepatitis C or B. The recurrence rate is very high and causes disease progression to an advanced stage. Recent development of molecularly targeted agents for the treatment of advanced HCC has dramatically changed the chemotherapies used for this disease. We summarize the current findings on several drugs that are commonly used for the treatment of advanced HCC including sorafenib and hepatic arterial infusion chemotherapies.

Entities:  

Keywords:  Antineoplastic agents; Hepatocellular carcinoma; Targeted therapy

Year:  2013        PMID： 26181443     DOI： 10.1007/s12328-013-0363-4

Source DB:  PubMed          Journal:  Clin J Gastroenterol        ISSN： 1865-7265


  52 in total

1.  5-fluorouracil arterial infusion + interferon therapy for highly advanced hepatocellular carcinoma: A multicenter, randomized, phase II study.

Authors:  Morito Monden; Masato Sakon; Yuh Sakata; Yoshitaka Ueda; Etsuro Hashimura
Journal:  Hepatol Res       Date:  2011-11-02       Impact factor: 4.288

2.  EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma.

Authors: 
Journal:  Eur J Cancer       Date:  2012-03       Impact factor: 9.162

3.  Predicting the treatment effect of sorafenib using serum angiogenesis markers in patients with hepatocellular carcinoma.

Authors:  Koji Miyahara; Kazuhiro Nouso; Takeshi Tomoda; Sayo Kobayashi; Hiroaki Hagihara; Kenji Kuwaki; Junichi Toshimori; Hideki Onishi; Fusao Ikeda; Yasuhiro Miyake; Shinichiro Nakamura; Hidenori Shiraha; Akinobu Takaki; Kazuhide Yamamoto
Journal:  J Gastroenterol Hepatol       Date:  2011-11       Impact factor: 4.029

4.  Management of hepatocellular carcinoma in Japan: Consensus-Based Clinical Practice Guidelines proposed by the Japan Society of Hepatology (JSH) 2010 updated version.

Authors:  Masatoshi Kudo; Namiki Izumi; Norihiro Kokudo; Osamu Matsui; Michiie Sakamoto; Osamu Nakashima; Masamichi Kojiro; Masatoshi Makuuchi
Journal:  Dig Dis       Date:  2011-08-09       Impact factor: 2.404

5.  Tissue platinum concentration and tumor response in non-small-cell lung cancer.

Authors:  Eric S Kim; J Jack Lee; Guangan He; Chi-Wan Chow; Junya Fujimoto; Neda Kalhor; Stephen G Swisher; Ignacio I Wistuba; David J Stewart; Zahid H Siddik
Journal:  J Clin Oncol       Date:  2012-08-13       Impact factor: 44.544

Review 6.  Improved chemotherapy for hepatocellular carcinoma.

Authors:  Huynh Cao; Hung Phan; Li-Xi Yang
Journal:  Anticancer Res       Date:  2012-04       Impact factor: 2.480

7.  First interim analysis of the GIDEON (Global Investigation of therapeutic decisions in hepatocellular carcinoma and of its treatment with sorafeNib) non-interventional study.

Authors:  R Lencioni; M Kudo; S-L Ye; J-P Bronowicki; X-P Chen; L Dagher; J Furuse; J F Geschwind; L Ladrón de Guevara; L L de Guevara; C Papandreou; A J Sanyal; T Takayama; S K Yoon; K Nakajima; F Cihon; S Heldner; J A Marrero
Journal:  Int J Clin Pract       Date:  2012-07       Impact factor: 2.503

Review 8.  Molecularly targeted therapy for advanced hepatocellular carcinoma in 2012: current status and future perspectives.

Authors:  Andrew X Zhu
Journal:  Semin Oncol       Date:  2012-08       Impact factor: 4.929

9.  Hepatic arterial infusion chemotherapy for hepatocellular carcinoma with portal vein tumor thrombosis.

Authors:  Yung-Chih Lai; Cheng-Yen Shih; Chin-Ming Jeng; Sien-Sing Yang; Jui-Ting Hu; Yung-Chuan Sung; Han-Ting Liu; Shaw-Min Hou; Chi-Hwa Wu; Tzen-Kwan Chen
Journal:  World J Gastroenterol       Date:  2003-12       Impact factor: 5.742

10.  Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study.

Authors:  Armando Santoro; Lorenza Rimassa; Ivan Borbath; Bruno Daniele; Stefania Salvagni; Jean Luc Van Laethem; Hans Van Vlierberghe; Jörg Trojan; Frank T Kolligs; Alan Weiss; Steven Miles; Antonio Gasbarrini; Monica Lencioni; Luca Cicalese; Morris Sherman; Cesare Gridelli; Peter Buggisch; Guido Gerken; Roland M Schmid; Corrado Boni; Nicola Personeni; Ziad Hassoun; Giovanni Abbadessa; Brian Schwartz; Reinhard Von Roemeling; Maria E Lamar; Yinpu Chen; Camillo Porta
Journal:  Lancet Oncol       Date:  2012-11-20       Impact factor: 41.316
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.